WASHINGTON--(BUSINESS WIRE)--Corindus, developer and marketer of proprietary remote control catheterization systems, announced today that it filed its Investigational Device Exemption (IDE) application for the CORRECT (Coronary Remote Control Catheterization Trial) clinical trial at the Cardiovascular Research Foundation’s eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.
